JB Pharma Sees Muted Q4, Bets On Integration-Led Recovery In FY27

Nikunj Parikh - Mumbai Bureau May 11, 2026 3,600 Views

JB Chemicals and Pharmaceuticals (JB Pharma) reported a soft Q4 FY26 with lower revenue and profit, but management reiterated confidence in an integration-led recovery from H1 FY27, backed by margin resilience and robust India formulations growth.

JB Pharma posted consolidated revenue from operations of Rs 904 crore and net profit of Rs 101 crore for Q4 FY26, impacted by one-offs linked to post-acquisition integration and network optimisation. Adjusted PAT stood at Rs 150 crore, reflecting the underlying strength of the core business despite temporary disruptions.

Operational Snapshot For The Quarter

For Q4 FY26, revenue declined 5% year-on-year to Rs 904 crore, while EBITDA was stable at Rs 241 crore with an improved EBITDA margin of 27% on the back of a stronger gross margin profile of 70%. Net profit after tax came in at Rs 101 crore versus Rs 146 crore a year ago, as exceptional items of Rs 27 crore and higher non-cash ESOP costs weighed on the bottom line.

Business Segment Performance

India business grew 2% year-on-year in the quarter to Rs 526 crore, and 9% for FY26 to Rs 2,461 crore, with branded generics and chronic portfolio outpacing overall IPM growth. International formulations de-grew 9% in Q4 to Rs 259 crore, impacted by inventory rationalisation, tighter credit practices and shipment delays, though FY26 international revenue still grew 2% to Rs 1,154 crore. CDMO revenue fell 22% in Q4 on a high base, and was flat at Rs 445 crore for the full year as customers reduced inventory.

Integration, Margins And Outlook

Management highlighted that Q4 reflects a “transient but important” integration phase, with distribution network optimisation, exit from low-margin trade generics and alignment of cut-off, credit and incentive policies with the Torrent Group parent. Despite revenue pressure, JB Pharma delivered significant improvement in gross and EBITDA margins due to cost synergies and a better business mix, and expects progressive performance improvement from April onwards as operational resets normalise.

Key highlights

Revenue from operations Q4 FY26: Rs 904 crore
Consolidated net profit Q4 FY26: Rs 101 crore; adjusted PAT Rs 150 crore
EBITDA Q4 FY26: Rs 241 crore; EBITDA margin 27%, gross margin 70%
FY26 revenue: Rs 4,148 crore; PAT Rs 709 crore; EBITDA Rs 1,195 crore
India business Q4: Rs 526 crore; FY26: Rs 2,461 crore, 9% YoY growth
International formulations Q4: Rs 259 crore; FY26: Rs 1,154 crore, 2% YoY growth
CDMO FY26 revenue: Rs 445 crore, flat year-on-year
One-offs: CFA restructuring, labour code impact, ESOP charges, trade generics rationalisation, policy alignment

Sources: Company press release, JB Chemicals and Pharmaceuticals Q4 FY26 results filing

Stay Ahead – Explore Now! Policy Proof: Modi 3.0 Solidifies Strategy to Defeat Homegrown Terror